Management of Large B-Cell Lymphomas: A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy

To participate in this activity, please:

B-cell lymphomas consist of a heterogenous group of lymphoproliferative neoplasms originating from B-lymphocytes. Large B-cell lymphomas (LBCLs) are one of the most common subtypes of non-Hodgkin lymphomas and while 1st-line standard of care has remained unchanged, the treatment paradigm has undergone a shift in recent years due to the development of novel therapeutic agents. These novel therapies include monoclonal antibody (mAb) therapies, mAb-conjugates, and chimeric antigen receptor (CAR)-T cell therapies. Management of relapsed/refractory LBCLs remains a substantial and persistent clinical challenge, including optimal treatment sequencing, therapy evaluation and patient selection, and toxicity management. In this activity, Jeremy Abramson, MD, highlights the significant disease burden of B-cell lymphomas, as well as the latest advances in therapeutics, and practical strategies for integrating novel therapies into practice through patient selection and supportive care management.

This program is also available as a podcast. You may download it here:

Course Credit:

1.00 ACPE Contact Hour
1.00 AMA PRA Category 1 CreditTM
1.00 ANCC Contact Hour


Opens: 2022-06-14
Closes: 2023-06-14

Target Audience:

This activity was developed for regional and national audiences of hematologist-oncologists, pathologists, histologists, advanced practitioners, oncology nurses, pharmacists, and other healthcare professionals involved in the care of patients diagnosed with large B-cell lymphomas (LBCL).

This activity is being supported by an educational grant from Bristol Myers Squibb.

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #. This program is designated for up to 1.00 hour (0.1 CEUs) of continuing pharmacy education credit.
Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 1.00 contact hour may be earned for successful completion of this activity.

Additional Content Planners

Christopher Elder, PharmD, BCOP (Medical Writer)

Advisory Board: Bristol Myers Squibb, Genentech, Mirati, Pfizer, Pharmacosmos, Sanofi

Heather M. Jimenez, FNP-C (Nurse Reviewer)
No significant relationships to disclose.

Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Jeremy Abramson, MD

    Director, Lymphoma Program
    Jon and Jo Ann Hagler Chair in Lymphoma
    Massachusetts General Hospital Cancer Center
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

Learning Objectives

  • Review the disease state, clinical and molecular heterogeneity, and unmet needs, including the clinical and healthcare resource burden, of LBCL
  • Describe the mechanism of action and appraise available clinical safety and efficacy data and indications for new agents for the treatment of LBCL, especially R/R LBCL, to select optimal treatments
  • Integrate approaches for identifying patients eligible for chimeric antigen receptor T-cell (CAR T-cell) therapy and applying suitable bridging therapies
  • Incorporate approaches for identifying, monitoring, and managing therapy-associated toxicities and AEs, including CAR T-cell–associated toxicities, for patients with LBCL

Faculty Disclosures

Jeremy Abramson, MD

Advisory Board: AbbVie, Century Therapeutics, Lilly, Mustang Bio, Regeneron

Consultant: AstraZeneca, BeiGene, Bristol Myers Squibb, Bluebird Bio, Epizyme, Genentech, Genmab, Incyte, Kite Pharma, Kymera, MorphoSys, Ono Pharma